Printer Friendly

IMMUNOGEN OPENS A NEW MANUFACTURING FACILITY IN CANTON, MASSACHUSETTS

 CAMBRIDGE, Mass., July 29 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today opens a 31,000-square-foot manufacturing plant in Canton, Mass. This new production facility will produce monoclonal antibodies for use in the company's Oncolysin(R) portfolio of products for cancer therapy.
 "ImmunoGen is a rapidly maturing company," states Mitchel Sayare, chairman and chief executive officer. "We have two Oncolysin products in advanced clinical trials in the treatment of cancer. Over all, four Oncolysins are in human testing. As we prepare for the commercial phase of operations, maintaining the availability and quality of the components used in our products -- at a reasonable and predictable cost -- becomes especially critical. Bringing in-house the capabilities for large-scale manufacture of monoclonal antibodies assures control over the quality and cost of these important raw materials."
 Each Oncolysin product is comprised of a monoclonal antibody conjugated to blocked ricin, a proprietary derivative of a potent plant toxin. The monoclonal antibody directs the cell-killing power of blocked ricin specifically to tumor cells, while leaving other cells unaffected. "Monoclonal antibody produced in this new facility will be used in the final product manufacturing process, conducted at our existing plant in Norwood, Mass.," Sayare explains. "We expect to use additional production suites in the Canton building to manufacture our next-generation small-drug conjugates, which are now in development for the treatment of solid tumors and for long-term cancer maintenance therapy. With these two facilities on-line, we have in place the means to meet our manufacturing needs for the next several years -- an important element in ImmunoGen's long-range corporate strategic planning."
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins and drugs conjugated to highly specific targeting agents which search out and destroy cancer cells. ImmunoGen's first- generation products, the Oncolysin portfolio of immunoconjugates, are designed for use in patients with minimal residual disease following conventional therapies. Oncolysin B, the company's lead product, is in Phase III clinical testing in the treatment of B-cell lymphomas. ImmunoGen's second product, Oncolysin S, has completed Phase I/II trials in the treatment of small-cell lung cancer.
 -0- 7/29/93
 /CONTACT: Mark Ratner, director of external communications for ImmunoGen, Inc., 617-661-9312/
 (IMGN)


CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU:

JL -- NE001 -- 7120 07/29/93 08:41 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1993
Words:382
Previous Article:INNOVATIVE GAMING CORPORATION OF AMERICA ANNOUNCES RESULTS OF LIVE VIDEO CRAPS MACHINE AT ITS BETA TEST LOCATION
Next Article:TELOR OPHTHALMIC PHARMACEUTICALS, INC. INITIATES PHASE II CLINICAL TRIALS TO EVALUATE TEKRON AS A NEW TREATMENT FOR GLAUCOMA
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters